Leuven

• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity … Ended
  2024-511511-25-00 9 2018-10-12 Resectable, locally advanced squamous cell carcinoma of the oral cavit
• Comparison of treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus p … Ended
  2024-517572-38-00 6 2018-10-03 cataract
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 5 2018-09-27 Moderately to Severely Active Crohn's Disease
• RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol … Ended
  2023-510189-28-00 6 2018-05-15 Rheumatoid Arthritis
• PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStem Ended
  2022-500251-22-00 4 2018-04-12 This study will include all patients having received at least one infu
• The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Ended
  2024-518736-37-00 6 2018-01-12 Risk of stroke by Atrial Fibrillation
• Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc … Ended
  2024-513167-68-00 5 2017-11-29 endometrial cancer
• Perioperative treatment of locally advanced resectable gastric or GEJ adenocarcinoma Ended
  2023-509595-42-00 5 2017-10-31 Gastric and gastroesophageal junction (GEJ) adenocarcinoma
• A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who … Ended
  2023-510557-42-00 4 2017-07-10 chronic lymphocytic leukemia
• A research study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patients Ended
  2024-514698-23-00 5 2017-05-15 Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Sk
• A study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Risdiplam in adult and pediatric patients with spi … Ended
  2023-506739-14-00 4 2017-05-12 Spinal Muscular Atrophy (SMA)
• A study to determine the effectiveness, safety, and tolerability of the Recombinant Von Willebrand Factor administered with or without Advat … Ended
  2023-509769-18-00 5 2017-03-15 Hereditary severe von Willebrand Disease in children
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar … Ended
  2023-508010-42-00 5 2016-09-14 Homologous recombination deficiency advanced ovarian cancer
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 5 2014-11-19 Advanced or metastatic renal cell carcinoma
• BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended
  2024-518931-12-00 4 2014-05-15 Neuroblastoma
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) Ended
  2022-501106-35-00 5 Obesity Overweight
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api
• Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended
  2022-502316-36-00 11 Symptomatic Obstructive Hypertrophic Cardiomyopathy
• Brightline-4: A study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma Ended
  2023-504522-19-00 5 dedifferentiated liposarcoma
• Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended
  2023-505070-15-00 9 Oncology, NSCLC and CRC

Showing 1,105–1,128 of 1,135 trials